O S Cohen1,2, J Chapman1,2, A D Korczyn2, N Warman-Alaluf1, Z Nitsan3, S Appel3, E Kahana3, H Rosenmann4. 1. Department of Neurology, The Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel. 2. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Barzilai Medical Center, Ashkelon, Israel. 4. Hadassah University Hospital, Jerusalem, Israel.
Abstract
BACKGROUND: Creutzfeldt-Jakob disease (CJD) is the most common prion disease in humans. The clinical diagnosis of CJD is supported by a combination of electroencephalogram, MRI, and the presence in the CSF of biomarkers. CSF tau is a marker for neuronal damage and tangle pathology, and is correlated with cognitive status in Alzheimer's disease (AD). OBJECTIVES: The aim of this study was to test whether tau levels in the CSF also correlate with the degree of the neurological deficit and cognitive decline in patients with CJD as reflected by various clinical scales that assess disease severity and cognitive performance. METHODS: Consecutive patients with familial CJD (fCJD) were examined by a neurologist who performed several tests including minimental status examination (MMSE), frontal assessment battery (FAB), NIH stroke scale (NIHSS), CJD neurological scale (CJD-NS), and the expanded disability status scale (EDSS). CSF tau was tested as part of the workout, and the correlation was tested using Pearson correlation. RESULTS: Fifty-two patients with fCJD were recruited to the study (35 males, mean age 59.4 ± 5.7, range 48-75 years). A significant negative correlation was found between CSF tau levels and the cognitive performance of the patients as reflected by their MMSE and FAB scores. In addition, a significant positive correlation was found between tau levels and the clinical disease severity scales of CJD-NS, NIHSS, and EDSS. CONCLUSION: The correlation between tau levels and the disease severity and degree of cognitive decline in patients with fCJD suggests that tau can be a biomarker reflecting the extent of neuronal damage.
BACKGROUND: Creutzfeldt-Jakob disease (CJD) is the most common prion disease in humans. The clinical diagnosis of CJD is supported by a combination of electroencephalogram, MRI, and the presence in the CSF of biomarkers. CSF tau is a marker for neuronal damage and tangle pathology, and is correlated with cognitive status in Alzheimer's disease (AD). OBJECTIVES: The aim of this study was to test whether tau levels in the CSF also correlate with the degree of the neurological deficit and cognitive decline in patients with CJD as reflected by various clinical scales that assess disease severity and cognitive performance. METHODS: Consecutive patients with familial CJD (fCJD) were examined by a neurologist who performed several tests including minimental status examination (MMSE), frontal assessment battery (FAB), NIH stroke scale (NIHSS), CJD neurological scale (CJD-NS), and the expanded disability status scale (EDSS). CSF tau was tested as part of the workout, and the correlation was tested using Pearson correlation. RESULTS: Fifty-two patients with fCJD were recruited to the study (35 males, mean age 59.4 ± 5.7, range 48-75 years). A significant negative correlation was found between CSF tau levels and the cognitive performance of the patients as reflected by their MMSE and FAB scores. In addition, a significant positive correlation was found between tau levels and the clinical disease severity scales of CJD-NS, NIHSS, and EDSS. CONCLUSION: The correlation between tau levels and the disease severity and degree of cognitive decline in patients with fCJD suggests that tau can be a biomarker reflecting the extent of neuronal damage.
Authors: Katie E Osborn; Dandan Liu; Lauren R Samuels; Elizabeth E Moore; Francis E Cambronero; Lealani Mae Y Acosta; Susan P Bell; Michelle A Babicz; Elizabeth A Gordon; Kimberly R Pechman; L Taylor Davis; Katherine A Gifford; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: Neurobiol Aging Date: 2018-04-03 Impact factor: 4.673
Authors: Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova Journal: Mol Neurobiol Date: 2016-09-24 Impact factor: 5.590
Authors: Stephanie J B Vos; Brian A Gordon; Yi Su; Pieter Jelle Visser; David M Holtzman; John C Morris; Anne M Fagan; Tammie L S Benzinger Journal: Neurobiol Aging Date: 2016-04-04 Impact factor: 4.673
Authors: Peter Hermann; Brian Appleby; Jean-Philippe Brandel; Byron Caughey; Steven Collins; Michael D Geschwind; Alison Green; Stephane Haïk; Gabor G Kovacs; Anna Ladogana; Franc Llorens; Simon Mead; Noriyuki Nishida; Suvankar Pal; Piero Parchi; Maurizio Pocchiari; Katsuya Satoh; Gianluigi Zanusso; Inga Zerr Journal: Lancet Neurol Date: 2021-03 Impact factor: 44.182
Authors: Kyan Younes; Julio C Rojas; Amy Wolf; Goh M Sheng-Yang; Matteo Paoletti; Gianina Toller; Eduardo Caverzasi; Maria Luisa Mandelli; Ignacio Illán-Gala; Joel H Kramer; Yann Cobigo; Bruce L Miller; Howard J Rosen; Michael D Geschwind Journal: Ann Clin Transl Neurol Date: 2021-05-05 Impact factor: 4.511
Authors: Andrew Geoffrey Bourne Thompson; Connie Luk; Amanda J Heslegrave; Henrik Zetterberg; Simon H Mead; John Collinge; Graham S Jackson Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-27 Impact factor: 10.154
Authors: Lucas M Ascari; Stephanie C Rocha; Priscila B Gonçalves; Tuane C R G Vieira; Yraima Cordeiro Journal: Front Bioeng Biotechnol Date: 2020-10-20